Contineum Q2 cash $218.7M; R&D $7.9M; IPO net $107.9M; Phase 2 enrollment on track

Contineum Therapeutics, Inc.

2024-Q2 EPS reported -$1.35

Cash, equivalents and marketable securities $218.7M at June 30, 2024, up from $125.2M at YE 2023.
R&D expenses $7.9M in Q2, down from $9.5M YoY, driven by lower consulting/manufacturing offset by Phase 2 costs.
G&A expenses $3.0M, up from $1.6M YoY on higher consulting and personnel costs.
IPO completed in April 2024 with net proceeds of $107.9M.
Enrollment ongoing in Phase 2 VISTA trial of PIPE-307 for RRMS; expects completion in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.